Intratumoral Immunotherapy: Is It Ready for Prime Time?

Authors :: Ghosn M
Tselikas L
Champiat S
Deschamps F
Bonnet B
Carre É
Testan M
Danlos FX
Farhane S
Susini S
Suzzoni S
Ammari S
Marabelle A
De Baere T
Source :: Current oncology reports [Curr Oncol Rep] 2023 Aug; Vol. 25 (8), pp. 857-867. Date of Electronic Publication: 2023 May 02.
Publication Year :: 2023
Abstract: Purpose of Review: This review presents the rationale for intratumoral immunotherapy, technical considerations and safety. Clinical results from the latest trials are provided and discussed.<br />Recent Findings: Intratumoral immunotherapy is feasible and safe in a wide range of cancer histologies and locations, including lung and liver. Studies mainly focused on multi-metastatic patients, with some positive trials such as T-VEC in melanoma, but evidence of clinical benefit is still lacking. Recent results showed improved outcomes in patients with a low tumor burden. Intratumoral immunotherapy can lower systemic toxicities and boost local and systemic immune responses. Several studies have proven the feasibility, repeatability, and safety of this approach, with some promising results in clinical trials. The clinical benefit might be improved in patients with a low tumor burden. Future clinical trials should focus on adequate timing of treatment delivery during the course of the disease, particularly in the neoadjuvant setting.<br /> (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)